Zenicor (ZENI) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
13 Jun, 2025Executive summary
Revenue for Q2 2024 reached 6,430 KSEK, a 3% increase year-over-year, marking the highest Q2 revenue to date.
EBITDA for Q2 2024 was 1,104 KSEK, up from 127 KSEK in Q2 2023.
Operating profit turned positive at 118 KSEK, compared to -438 KSEK in Q2 2023.
Revenue has increased for 13 consecutive quarters.
Growth was impacted by delayed procurements in Sweden and Finland, but cost adjustments and new loans have strengthened liquidity.
Financial highlights
Revenue for Q2 2024: 6,430 KSEK (6,238 KSEK in Q2 2023).
EBITDA for Q2 2024: 1,104 KSEK (127 KSEK in Q2 2023).
Operating profit for Q2 2024: 118 KSEK (-438 KSEK in Q2 2023).
Earnings per share for Q2 2024: 0.01 SEK (-0.05 SEK in Q2 2023).
Net result for Q2 2024: -430 KSEK (-911 KSEK in Q2 2023).
Outlook and guidance
Targeting a 20% growth rate within 6–12 months, with positive full-year results expected.
Q3 revenue is seasonally lower, but Q4 is expected to show accelerating growth.
Cost adjustments and improved cash flow are expected to reduce total loan debt from Q3 2024.
Latest events from Zenicor
- Strong revenue growth and profitability in 2025, with robust outlook for 2026.ZENI
Q4 202513 Feb 2026 - Rights issue and new contracts support rapid growth in arrhythmia diagnostics and early care.ZENI
Investor Update4 Nov 2025 - Q3 2025 revenue up 10% year-over-year, with positive profit and new growth financing secured.ZENI
Q3 202527 Oct 2025 - Q2 2025 saw 10% revenue growth, positive profit, and key wins in Finland and the UK.ZENI
Q2 202531 Jul 2025 - Revenue growth and positive operating income mark a strong Q3, despite liquidity challenges.ZENI
Q3 202413 Jun 2025 - Record Q1 revenue and UK contracts drive Zenicor's return to profitability.ZENI
Q1 20256 Jun 2025 - Record revenue and a return to profit set the stage for accelerated growth in 2025.ZENI
Q4 20246 Jun 2025